Biological
Recombinant human interleukin-2
Recombinant human interleukin-2 is a biological therapy with 3 clinical trials. Historical success rate of 50.0%.
Total Trials
3
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Clinical Success Rate
50.0%
Based on 1 completed trials
Completion Rate
50%(1/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(33%)
Phase Distribution
Ph phase_1
3
100%
Phase Distribution
3
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
3(100.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
50.0%
1 of 2 finished
Non-Completion Rate
50.0%
1 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(1)
Terminated(1)
Other(1)
Detailed Status
Completed1
Terminated1
unknown1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
50.0%
Most Advanced
Phase 1
Trials by Phase
Phase 13 (100.0%)
Trials by Status
completed133%
terminated133%
unknown133%
Recent Activity
0 active trials
Showing 3 of 3
completedphase_1
ACTolog in Patients With Solid Cancers
NCT02876510
terminatedphase_1
CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma
NCT05207722
unknownphase_1
T Cell Mediated Adaptive Therapy for Her2-positive Neoplasms of Digestive System
NCT02662348
Clinical Trials (3)
Showing 3 of 3 trials
NCT02876510Phase 1
ACTolog in Patients With Solid Cancers
NCT05207722Phase 1
CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma
NCT02662348Phase 1
T Cell Mediated Adaptive Therapy for Her2-positive Neoplasms of Digestive System
All 3 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 3